HORIBA

Summary of Consolidated Financial Statements for the Six Months Ended June 30, 2024 (Japanese GAAP)

[Note : This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.]

Company name	HORIBA, Lto	I.
--------------	-------------	----

Listing code6856RepresentativeMasayuki Adachi, President & COOContactToyota Uenaka, Department Manager, Finance and Accounting Dept.Scheduled date of start of interim dividend payment: September 2, 2024

August 8, 2024 Listed stock exchanges: Tokyo URL: https://www.horiba.com/int/ TEL: (81)75-313-8121

(Figures have been rounded down to the nearest million yen)

1. Consolidated Results for the Six Months Ended June 30, 2024 (January 1, 2024 - June 30, 2024) (1) Consolidated Operating Results (Percentages represent changes from the corresponding in the previous year)

(T) Consolidated Operating Results (Percentages rep					nt changes from t	ne corres	sponding in the previo	jus year)
	Net Sales		Operating Income		Ordinary Income		Net Income Attributable to HORIBA Ltd.'s Shareholders	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six Months Ended 6/30/24	142,720	8.9	18,615	4.4	19,266	6.3	13,148	-30.8
Six Months Ended 6/30/23	131,105	14.0	17,838	9.7	18,124	8.0	19,006	69.1
(Nata) Camanahanaiya inaamay	EV/202402	20 754	mailliana viana (4 4 0 /)		22.2	00 million von (00	

(Note) Comprehensive income: FY2024Q2 33,754 million yen (1.1%) FY2023Q2 33,392 million yen (38.0%)

	Net Income Attributable to HORIBA Ltd.'s Shareholders per Share	Net Income Attributable to HORIBA Ltd.'s Shareholders per Share (Diluted)
	Yen	Yen
Six Months Ended 6/30/24	312.43	310.83
Six Months Ended 6/30/23	449.87	447.66

(2) Consolidated Financial Position

Total Assets	Net Assets	Shareholders' Equity Ratio
Millions of yen	Millions of yen	%
469,349	303,780	64.6
449,030	283,732	63.0
	Millions of yen 469,349	Millions of yen Millions of yen 469,349 303,780 449,030 283,732

(Reference) Net assets excluding subscription rights to shares and non-controlling interests: As of 6/30/24 303,089 million yen As of 12/31/23 283,008 million yen

2. Dividends

		Dividend per Share						
	First Quarter	Second Quarter	Third Quarter	Year End	Total			
	Yen	Yen	Yen	Yen	Yen			
FY 12/2023	-	80.00	-	210.00	290.00			
FY 12/2024	-	80.00						
FY 12/2024 (Forecast)			-	185.00	265.00			

(Note) Changes in the latest dividend forecasts released: None

3. Consolidated Forecasts for the Year Ending December 31, 2024 (January 1, 2024 - December 31, 2024)

(Percentages represent changes from the previous fiscal year)

	Net Sales		Operating In	come	Ordinary Income		Net Income Attrib to HORIBA Lto Shareholder	d.'s	Net Income Attributable to HORIBA Ltd.'s Shareholders per Share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full Year	321,000	10.5	52,000	9.9	52,700	9.2	37,000	-8.2	881.95

(Note) Changes in the latest business forecasts released: None

Notes

- (1) Changes in significant subsidiaries during the period
 - (Changes in specified subsidiaries that caused a change in the scope of consolidation): None
- (2) Application of the accounting method specific to interim consolidated financial statements: Yes
- (3) Changes in accounting policies, accounting estimates and retrospective restatement
 - (i) Changes in accounting policies associated with revision of accounting standards: None
 - ($\rm ii$) Changes in accounting policies arising from other than the above: None
 - (iii) Changes in accounting estimates: None
 - (iv) Retrospective restatement: None
- (4) Number of shares outstanding (common stock)

($\rm i$) Shares issued (including treasury stock)	June 30, 2024	42,233,252	December 31, 2023	42,532,752
(ii) Treasury stock	June 30, 2024	280,649	December 31, 2023	263,029
(iii) Average number of outstanding shares	Jan Jun., 2024	42,085,539	Jan Jun., 2023	42,247,766

Note 1. This consolidated financial report is not subject to review by certified public accountants or accounting firms. Note 2. Appropriate use of business forecasts and other important information

The forecasts of dividend amount and business performance contained in this report have been made based on certain future assumptions, outlooks, and plans which are available at the HORIBA Group as of August 8, 2024. However, due to risks and various uncertain factors such as future business operation policies, changes in the economic environment in Japan and overseas, fluctuation of currency rates, it is possible that actual performance would vary considerably from the forecasts.

1. Qualitative Information Concerning Consolidated Results

(1) Information Concerning Consolidated Operating Results

(For details, see pages 12-14, "3. Supplemental Information - HORIBA, Ltd. Financial Highlights for the Six Months Ended June 30, 2024")

During the six months ended June 30, 2024, HORIBA, Ltd. (hereinafter the Company) and its consolidated subsidiaries (hereinafter the HORIBA Group or HORIBA) increased sales by 8.9% year-on-year to 142,720 million yen. Sales growth was mainly due to the depreciation of the yen against the euro and dollar, which boosted sales when translated into yen, and an increase in sales in the Automotive segment. Operating income increased by 4.4% to 18,615 million yen and ordinary income increased by 6.3% to 19,266 million yen.

Net income attributable to HORIBA Ltd.'s shareholders decreased by 30.8% to 13,148 million yen, mainly due to extraordinary gain on the sale of shares of subsidiaries of 6,297 million yen recognized in the first six months of FY2023.

The operating results of each business segment are summarized as follows.

(Automotive Segment)

Mainly due to an increase in sales of emission measurement systems and MCT(Mechatronics) business in Japan and the Americas, segment sales increased by 26.4% year-on-year to 38,620 million yen. On the profit side, continuous investments in the hydrogen related field resulted in an operating loss of 1,169 million yen, while in the first six months of FY2023 an operating loss was 2,159 million yen.

(Process & Environmental Segment)

Despite the sales of air pollution analyzers were sluggish in Europe, an increase in sales of process gas analyzers and water quality systems in Japan contributed to boosting segment sales by 3.3% year-on-year to 11,709 million yen. Operating income decreased by 82.3% to 162 million yen due to a decrease in sales in Europe and the investment burden associated with the set-up in the industrial process monitoring business, which the Company acquired in the fourth quarter of FY2023.

(Medical-Diagnostics Segment)

Segment sales increased by 4.9% year-on-year to 16,350 million yen, as the depreciation of the yen. On the profit side, partly due to a decrease in sales in Japan resulted in an operating loss of 456 million yen, while in the first six months of FY2023 an operating income was 178 million yen.

(Semiconductor Segment)

Capital expenditures of semiconductor manufacturers have shown a certain level of recovery. Segment sales increased by 1.8% year-on-year to 57,256 million yen thanks to an increase in sales to semiconductor production equipment manufacturers in Asia. Operating income increased by 8.4% to 20,254 million yen due to the depreciation of the yen and an increase in sales in Asia.

(Scientific Segment)

Mainly due to an increase in sales of Raman spectrometers for analysis of advanced materials in Asia and Europe, segment sales increased by 7.9% year-on-year to 18,783 million yen. However, the segment recorded an operating loss of 174 million yen, while it was an operating income of 213 million yen in the first six months of FY2023, due to a change in the product sales mix and an increase in R&D expenses to accelerate the development of new products.

(2) Information Concerning Consolidated Earnings Forecasts for FY2024

Our assumption for the exchange rate remains unchanged at 145 yen to the US dollar and 160 yen to the euro, given uncertainty about the future exchange rates.

Consolidated forecasts of FY2024 (Full year)

			Amount: Millions of yen
	Previous Forecasts (As of May 14)	Revised Forecasts (As of Aug. 8)	Changes
Net Sales	321,000	321,000	-
Operating Income	52,000	52,000	-
Ordinary Income	52,700	52,700	-
Net Income Attributable to HORIBA Ltd.'s Shareholders	37,000	37,000	-

Consolidated forecasts of FY2024 by segment (Full year)

Net Sales		Amount: Milli	ons of yen	Operating Income		Amount: Milli	ons of yen
	Previous Forecasts (As of May 14)	Revised Forecasts (As of Aug. 8)	Changes		Previous Forecasts (As of May 14)	Revised Forecasts (As of Aug. 8)	Changes
Automotive	94,000	94,000	-	Automotive	3,000	3,000	-
Process& Environmental	31,500	31,500	-	Process& Environmental	3,000	2,500	-500
Medical- Diagnostics	34,500	34,500	-	Medical- Diagnostics	1,000	500	-500
Semiconductor	119,000	119,000	-	Semiconductor	42,000	43,500	+1,500
Scientific	42,000	42,000	-	Scientific	3,000	2,500	-500
Total	321,000	321,000	-	Total	52,000	52,000	-

Overall sales forecasts remain unchanged for all segments. Regarding operating income forecasts, the Company has revised upward by 1,500 million yen for the Semiconductor segment, and downward by 500 million yen respectively, for the Process & Environmental segment, the Medical-Diagnostics segment and the Scientific segment, considering the consolidated results for the first half of FY2024.

As a result, the overall sales forecast, the operating income forecast, the ordinary income forecast and the net income attributable to HORIBA Ltd.'s shareholders forecast remain unchanged.

The dividend forecast for the current fiscal year remains unchanged.

Cautionary statement with respect to earnings forecasts

The forecasts of dividend amount and business performance contained in this report have been made based on certain future assumptions, outlooks, and plans which are available at the HORIBA Group as of August 8, 2024. However, due to risks and various uncertain factors such as future business operation policies, changes in the economic environment in Japan and overseas, fluctuation of currency rates, it is possible that actual performance would vary considerably from the forecasts.

2. Consolidated Financial Statements and Notes

(1) Consolidated Balance Sheets

	FY2023	Amount: Millions of ye FY2024 First Half
	(As of December 31, 2023)	(As of June 30, 2024)
Assets		
Current Assets:		
Cash and bank deposits	132,775	134,39
Notes and accounts receivable - trade, and contract assets	71,541	69,56
Marketable securities	2,000	2,00
Merchandise and finished goods	35,145	36,05
Work in process	24,696	29,43
Raw materials and supplies	39,632	44,31
Other current assets	14,102	14,95
Allowance for doubtful accounts	(1,317)	(2,897
Total Current Assets	318,577	327,84
Fixed Assets:		
Property, Plant and Equipment:		
Buildings and structures, net	55,454	57,94
Machinery, equipment and vehicles, net	17,652	19,53
Land	20,311	21,68
Construction in progress	2,530	4,91
Other property, plant and equipment, net	4,853	4,90
Total Property, Plant and Equipment	100,801	108,97
Intangibles:		
Goodwill	1,343	1,27
Software	1,258	1,06
Leasehold interests in land	629	69
Other intangibles	1,733	1,86
Total Intangibles	4,965	4,89
Investments and Other Non-Current Assets:		
Investment securities	15,666	18,10
Retirement benefit asset	1,212	1,24
Deferred tax assets	6,244	6,83
Other investments and other assets	2,778	1,50
Allowance for doubtful accounts	(1,214)	(54
Total Investments and Other Non-Current Assets	24,686	27,63
Total Fixed Assets	130,453	141,50
Total Assets	449,030	469,34

Amount: Millions of yen			
	FY2023	FY2024 First Half	
	(As of December 31, 2023)	(As of June 30, 2024)	
Liabilities			
Current Liabilities:			
Trade notes and accounts payable	30,518	18,822	
Short-term loans payable	5,695	11,830	
Accounts payable - other	22,184	21,154	
Accrued income taxes	5,783	6,238	
Contract liabilities	24,713	28,970	
Accrued bonuses to employees	2,312	1,449	
Accrued bonuses to directors and corporate auditors	-	529	
Reserve for product warranty	3,570	3,347	
Other current liabilities	6,272	7,319	
Total Current Liabilities	101,051	99,663	
Non-Current Liabilities:			
Corporate bonds	30,000	30,000	
Long-term loans payable	24,699	25,034	
Deferred tax liabilities	645	831	
Retirement benefit liability	1,873	2,164	
Other non-current liabilities	7,027	7,875	
Total Non-Current Liabilities	64,246	65,905	
Total Liabilities	165,298	165,568	
Net Assets			
Shareholders' Equity			
Common stock	12,011	12,011	
Capital surplus	18,766	18,624	
Retained earnings	223,320	224,740	
Treasury stock	(1,037)	(2,840)	
Total Shareholders' Equity	253,060	252,536	
Accumulated Other Comprehensive Income			
Net unrealized holding gains or losses on securities	6,850	8,354	
Foreign currency translation adjustments	22,785	41,916	
Remeasurements of defined benefit plans	312	282	
Total Accumulated Other Comprehensive Income	29,947	50,553	
Subscription Rights to Shares	706	673	
Non-Controlling Interests	17	17	
Total Net Assets	283,732	303,780	
Total Liabilities and Net Assets	449,030	469,349	

(2) Consolidated Statements of Income and Consolidated Comprehensive Income Statements (Consolidated Statements of Income)

		Amount: Millions of ye
	FY2023 First Half	FY2024 First Half
	(Six Months Ended June 30, 2023)	(Six Months Ended June 30, 2024)
Net Sales	131,105	142,720
Cost of Sales	74,971	80,654
Gross Income	56,134	62,065
Selling, General and Administrative Expenses	38,295	43,449
Operating Income	17,838	18,615
Non-Operating Income		
Interest income	715	1,238
Dividend income	146	169
Subsidy income	11	27
Other	170	175
Total Non-Operating Income	1,043	1,610
Non-Operating Expenses		
Interest expenses	332	438
Foreign exchange losses	373	313
Other	51	209
Total Non-Operating Expenses	757	960
Ordinary Income	18,124	19,266
Extraordinary Gain		
Gain on sales of fixed assets	12	10
Gain on sale of shares of subsidiaries	6,297	
Total Extraordinary Gain	6,309	10
Extraordinary Losses		
Loss on sales of fixed assets	-	(
Loss on disposal of fixed assets	29	25
Loss on sale of investment securities	0	
Loss on valuation of investment securities	21	
Total Extraordinary Losses	50	20
Income before Income Taxes	24,384	19,249
Income taxes (current)	6,566	6,716
Income taxes (deferred)	(1,191)	(615
Total Income Taxes	5,374	6,101
Net Income	19,009	13,148
Profit (loss) attributable to non-controlling interests	3	(0
Net Income Attributable to HORIBA Ltd.'s Shareholders	19,006	13,148

(Consolidated Statements of Comprehensive II	ncome)
--	--------

		,
	FY2023 First Half	FY2024 First Half
	(Six Months Ended	(Six Months Ended
	June 30, 2023)	June 30, 2024)
Net Income	19,009	13,148
Other Comprehensive Income		
Net unrealized holding gains or losses on securities	1,355	1,504
Foreign currency translation adjustments	12,844	18,951
Remeasurements of defined benefit plans	1	(29)
Share of other comprehensive income of entities accounted for	181	180
using equity method		100
Total Other Comprehensive Income	14,383	20,605
Comprehensive Income	33,392	33,754
(Breakdown of comprehensive income)		
Comprehensive income attributable to HORIBA Ltd.'s Shareholders	33,386	33,754
Comprehensive income attributable to non-controlling interests	6	(0)

(3) Consolidated Statements of Cash Flows

		Amount. Willions of yer
	FY2023 First Half	FY2024 First Half
	(Six Months Ended	(Six Months Ended
	June 30, 2023)	June 30, 2024)
Cash Flows from Operating Activities:		
Income before income taxes	24,384	19,249
Depreciation expense	5,751	6,375
Amortization of goodwill	247	215
Increase (decrease) in allowance for doubtful accounts	58	120
Increase (decrease) in retirement benefit liability	111	105
Interest and dividend income	(861)	(1,407)
Interest expense	332	438
Foreign exchange losses (gains)	(162)	70
Loss (gain) on sales of fixed assets	(12)	(9)
Loss on disposal of fixed assets	29	25
Loss (gain) on valuation of investment securities	21	-
Loss (gain) on sales of investment securities	0	-
Loss (gain) on sale of shares of subsidiaries	(6,297)	-
Decrease (increase) in notes and accounts receivable - trade, and contract assets	10,504	7,875
Decrease (increase) in inventories	(15,569)	(3,666)
Increase (decrease) in trade notes and accounts payable	(5,254)	(14,431)
Other, net	939	(871)
Subtotal	14,221	14,092
Interest and dividends received	844	1,458
Interest paid	(383)	(411)
Income taxes (paid) refund	(11,046)	(5,184)
Net Cash Provided by (Used in) Operating Activities	3,635	9,955

		Amount: Millions of yer
	FY2023 First Half	FY2024 First Half
	(Six Months Ended	(Six Months Ended
	June 30, 2023)	June 30, 2024)
Cash Flows from Investing Activities:		
Increase in time deposits	(1,461)	(790)
Decrease in time deposits	1,879	2,935
Payments for purchase of marketable securities	(1,000)	(1,005)
Proceeds from sales or redemption of marketable securities	500	1,003
Payments for purchase of property, plant and equipment	(4,613)	(6,523)
Proceeds from sales of property, plant and equipment	45	42
Payments for purchase of intangibles	(130)	(83)
Payments for purchase of investment securities	(10)	(10)
Proceeds from sales or redemption of investment securities	0	-
Payments of loans receivable	(9)	(15)
Collection of loans receivable	19	14
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(665)	-
Proceeds from sale of shares of subsidiaries resulting in change in scope of consolidation	4,233	-
Other, net	(63)	41
Net Cash Provided by (Used in) Investing Activities	(1,277)	(4,390)
Cash Flows from Financing Activities:		
Net increase (decrease) in short-term borrowings	(10,083)	5,273
Increase in long-term debt	-	45
Repayments of long-term debt	(113)	(215)
Repayments on finance lease obligations	(775)	(946)
Purchase of treasury shares	(0)	(5,016)
Proceeds from disposal of treasury shares	0	0
Cash dividends paid	(7,592)	(8,870)
Net Cash Provided by (Used in) Financing Activities	(18,565)	(9,730)
Effect of Exchange Rate Changes on Cash and Cash Equivalents	4,455	7,852
Net Increase (Decrease) in Cash and Cash Equivalents	(11,751)	3,686
Cash and Cash Equivalents at Beginning of Period	138,760	130,550
Cash and Cash Equivalents at End of Period	127,009	134,237

(4) Notes to Consolidated Financial Statements

Application of special accounting for preparing interim consolidated financial statement (Calculation method for tax expenses)

The Company and its domestic consolidated subsidiaries calculated income tax expenses by multiplying income before income taxes by reasonably estimated annual effective tax rate. This tax rate was reasonably estimated after applying the deferred tax accounting to the annual income before income taxes.

3. Supplemental Information

HORIBA, Ltd. Financial Highlights for the Six Months Ended June 30, 2024

1.Consolidated Financial Results

1.Consolidated Financial Results						A	mount : Millio	ons of yen
	12/2023 Results	12/2024 Results	Chanç	ges	12/2023 Results	12/2024 Forecasts	Chan	ges
	1st Half	1st Half	Amount	Ratio	Full Year	Full Year	Amount	Ratio
Net Sales	131,105	142,720	+11,614	+8.9%	290,558	321,000	+30,441	+10.5%
Operating Income	17,838	18,615	+777	+4.4%	47,296	52,000	+4,703	+9.9%
Operating Income Ratio	13.6%	13.0%	-0.6P		16.3%	16.2%	-0.1P	
Ordinary Income	18,124	19,266	+1,141	+6.3%	48,251	52,700	+4,448	+9.2%
Ordinary Income Ratio	13.8%	13.5%	-0.3P		16.6%	16.4%	-0.2P	
Net Income Attributable to HORIBA Ltd.'s Shareholders	19,006	13,148	-5,857	-30.8%	40,302	37,000	-3,302	-8.2%
Net Income Ratio	14.5%	9.2%	-5.3P		13.9%	11.5%	-2.4P	
US\$	135.00	152.36	+17.36		140.67	145.00	+4.33	
Euro	145.93	164.70	+18.77		152.11	160.00	+7.89	

2.Consolidated Segment Results

Amount : Millions of yen

Net Sales	12/2023 Results	12/2024 Results	Chang	jes	12/2023 Results	12/2024 Forecasts	Chang	jes
	1st Half	1st Half	Amount	Ratio	Full Year	Full Year	Amount	Ratio
Automotive	30,545	38,620	+8,074	+26.4%	80,406	94,000	+13,593	+16.9%
Process & Environmental	11,336	11,709	+373	+3.3%	24,959	31,500	+6,540	+26.2%
Medical-Diagnostics	15,592	16,350	+757	+4.9%	32,678	34,500	+1,821	+5.6%
Semiconductor	56,225	57,256	+1,030	+1.8%	112,872	119,000	+6,127	+5.4%
Scientific	17,404	18,783	+1,378	+7.9%	39,641	42,000	+2,358	+5.9%
Total	131,105	142,720	+11,614	+8.9%	290,558	321,000	+30,441	+10.5%

Operating Income	12/2023 Results	12/2024 Results	Chang	jes	12/2023 Results	12/2024 Forecasts	Chan	ges
	1st Half	1st Half	Amount	Ratio	Full Year	Full Year	Amount	Ratio
Automotive	(2,159)	(1,169)	+989	-	1,209	3,000	+1,790	+148.1%
Process & Environmental	916	162	-754	-82.3%	2,412	2,500	+87	+3.6%
Medical-Diagnostics	178	(456)	-635	-	638	500	-138	-21.7%
Semiconductor	18,689	20,254	+1,564	+8.4%	40,580	43,500	+2,919	+7.2%
Scientific	213	(174)	-388	-	2,456	2,500	+43	+1.8%
Total	17,838	18,615	+777	+4.4%	47,296	52,000	+4,703	+9.9%

HORIBA, Ltd. (Consolidated)

3.Consolidated Segment Sales by Destination

Amount : Millions of yen

	12/2022	12/2023 12/2024 Changes 12/2023 12/2024				12/2024		
-	Results	Results	Chan	ges	Results	Forecasts	Chan	ges
	1st Half	1st Half	Amount	Ratio	Full Year	Full Year	Amount	Ratio
Automotive	30,545	38,620	+8,074	+26.4%	80,406	94,000	+13,593	+16.9%
Japan	6,989	10,986	+3,996	+57.2%	16,868	20,800	+3,931	+23.3%
Asia	6,571	7,093	+521	+7.9%	19,761	20,500	+738	+3.7%
Americas	3,552	5,386	+1,833	+51.6%	10,637	12,400	+1,762	+16.6%
Europe	13,432	15,154	+1,722	+12.8%	33,138	40,300	+7,161	+21.6%
Process&Environmental	11,336	11,709	+373	+3.3%	24,959	31,500	+6,540	+26.2%
Japan	5,559	6,133	+573	+10.3%	11,446	13,100	+1,653	+14.4%
Asia	2,256	2,211	-44	-2.0%	5,863	9,300	+3,436	+58.6%
Americas	1,726	1,776	+50	+2.9%	3,689	4,000	+310	+8.4%
Europe	1,793	1,588	-205	-11.5%	3,960	5,100	+1,139	+28.8%
Medical-Diagnostics	15,592	16,350	+757	+4.9%	32,678	34,500	+1,821	+5.6%
Japan	3,401	3,126	-274	-8.1%	6,906	7,100	+193	+2.8%
Asia	3,599	3,894	+295	+8.2%	7,812	8,700	+887	+11.4%
Americas	3,609	3,541	-67	-1.9%	7,069	7,700	+630	+8.9%
Europe	4,983	5,788	+805	+16.2%	10,889	11,000	+110	+1.0%
Semiconductor	56,225	57,256	+1,030	+1.8%	112,872	119,000	+6,127	+5.4%
Japan	14,802	11,875	-2,927	-19.8%	27,343	31,000	+3,656	+13.4%
Asia	33,002	36,986	+3,983	+12.1%	69,052	67,200	-1,852	-2.7%
Americas	4,585	4,987	+402	+8.8%	9,266	15,000	+5,733	+61.9%
Europe	3,835	3,407	-428	-11.2%	7,209	5,800	-1,409	-19.5%
Scientific	17,404	18,783	+1,378	+7.9%	39,641	42,000	+2,358	+5.9%
Japan	4,113	4,071	-42	-1.0%	7,579	9,300	+1,720	+22.7%
Asia	5,540	6,714	+1,174	+21.2%	14,777	15,300	+522	+3.5%
Americas	4,709	4,597	-112	-2.4%	10,024	9,400	-624	-6.2%
Europe	3,041	3,400	+359	+11.8%	7,261	8,000	+738	+10.2%
Total	131,105	142,720	+11,614	+8.9%	290,558	321,000	+30,441	+10.5%
Japan	34,866	36,192	+1,325	+3.8%	70,144	81,300	+11,155	+15.9%
Asia	50,969	56,899	+5,930	+11.6%	117,266	121,000	+3,733	+3.2%
Americas	18,183	20,289	+2,106	+11.6%	40,687	48,500	+7,812	+19.2%
Europe	27,085	29,338	+2,252	+8.3%	62,458	70,200	+7,741	+12.4%

4. Capital Expenditures, Depreciation and R&D Expenses

Amount : Millions of yen

	12/2	023	12/2024			
	1st Half Results	Full-year Results	1st Half Results	Full-year Forecasts		
Capital Expenditures (*1)	4,269	9,122	6,267	23,000		
Depreciation (*2)	5,998	12,602	6,591	14,000		
R&D Expenses	9,827	20,436	11,187	22,600		

(*1) Capital Expenditures are investments in tangible and intangible fixed assets.

(*2) Amortization of goodwill is included in depreciation.

5. Consolidated Financial Results (Quarterly Comparison)

· · · · · · · · · · · · · · · · · · ·		12/2023 R	esults			12/2024	
-	1Q	2Q	3Q	4Q	1Q Results	2Q Results	2H Forecasts
Net Sales	65,854	65,251	69,574	89,878	70,252	72,468	178,279
Operating Income	10,450	7,387	10,660	18,797	10,009	8,606	33,384
Operating Income Ratio	15.9%	11.3%	15.3%	20.9%	14.2%	11.9%	18.7%
Ordinary Income	10,320	7,803	10,964	19,162	10,165	9,100	33,433
Ordinary Income Ratio	15.7%	12.0%	15.8%	21.3%	14.5%	12.6%	18.8%
Net Income Attributable to HORIBA Ltd.'s Shareholders	13,556	5,449	7,966	13,330	7,029	6,119	23,851
Net Income Ratio	20.6%	8.4%	11.4%	14.8%	10.0%	8.4%	13.4%

6. Consolidated Segment Results (Quarterly Comparison)

Amount : Millions of yen

Amount : Millions of yen

Net Sales		12/2023 R	esults			12/2024	
Net Sales	1Q	2Q	3Q	4Q	1Q Results	2H Forecasts	
Automotive	15,943	14,602	17,621	32,238	19,528	19,092	55,379
Process & Environmental	5,404	5,931	5,921	7,701	5,941	5,768	19,790
Medical-Diagnostics	7,351	8,241	7,815	9,270	7,641	8,709	18,149
Semiconductor	28,988	27,237	28,330	28,315	27,899	29,356	61,743
Scientific	8,166	9,238	9,884	12,352	9,242	9,540	23,216
Total	65,854	65,251	69,574	89,878	70,252	72,468	178,279

Operating Income		12/2023 Re	esults		12/2024			
Operating Income	1Q	2Q	3Q	4Q	1Q Results	2Q Results	2H Forecasts	
Automotive	330	(2,490)	(577)	3,946	178	(1,348)	4,169	
Process & Environmental	529	387	505	990	348	(186)	2,337	
Medical-Diagnostics	(43)	221	51	408	(316)	(139)	956	
Semiconductor	9,707	8,981	10,132	11,757	9,796	10,458	23,245	
Scientific	(73)	286	549	1,693	2	(177)	2,674	
Total	10,450	7,387	10,660	18,797	10,009	8,606	33,384	

Contact

Corporate Planning Office, Group Strategy Division, HORIBA, Ltd. E-mail: ir-info@horiba.com